Abstract
The potency of felbamate, an anti-convulsive drug, to influence dopamine D1 (SCH 23390) and D2 (haloperidol) receptor-mediated catalepsy (akinesia and bradykinesia) was studied in rats. In the catalepsy test, felbamate antagonized dopamine D2 receptor- but not D1 receptor-induced akinesia. Bradykinesia in the open field was never influenced. The results demonstrate that felbamate has similar anti-parkinsonian potential as glycine site antagonists blocking the N-methyl-D-aspartate (NMDA) receptor complex.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Anticonvulsants / pharmacology*
-
Antiparkinson Agents / pharmacology*
-
Benzazepines / pharmacology
-
Catalepsy / chemically induced
-
Dopamine D2 Receptor Antagonists
-
Dyskinesia, Drug-Induced / prevention & control
-
Felbamate
-
Haloperidol / pharmacology
-
Male
-
Phenylcarbamates
-
Propylene Glycols / pharmacology*
-
Rats
-
Rats, Sprague-Dawley
-
Receptors, Dopamine D1 / antagonists & inhibitors
Substances
-
Anticonvulsants
-
Antiparkinson Agents
-
Benzazepines
-
Dopamine D2 Receptor Antagonists
-
Phenylcarbamates
-
Propylene Glycols
-
Receptors, Dopamine D1
-
Haloperidol
-
Felbamate